<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375245</url>
  </required_header>
  <id_info>
    <org_study_id>14435B</org_study_id>
    <nct_id>NCT00375245</nct_id>
  </id_info>
  <brief_title>Rapamycin With Grapefruit Juice for Advanced Malignancies</brief_title>
  <official_title>A Phase Ib Study Administering Rapamycin (Sirolimus) With Grapefruit Juice in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the highest safe dose of rapamycin when given with
      a fixed amount of grapefruit juice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic interaction</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Tumors</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Rapamycin + Grapefruit juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin (sirolimus)</intervention_name>
    <description>Weekly oral doses, dose is assigned at the time of study entry</description>
    <arm_group_label>Rapamycin + Grapefruit juice</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Grapefruit Juice</intervention_name>
    <description>Daily oral doses starting during the second week on study.</description>
    <arm_group_label>Rapamycin + Grapefruit juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed malignancy that is metastatic or unresectable and for which
             standard curative or palliative measures do not exist or are no longer effective.

          -  Patients with hematologic malignancies (lymphoma, multiple myeloma and chronic
             lymphocytic leukemia (CLL) only) are eligible to participate in the phase IB portion
             of the trial only.

          -  At least 4 weeks since prior chemotherapy or radiation therapy

          -  Aged 18 years or older

          -  ECOG performance status 0-2

          -  Life expectancy of greater than 3 months.

          -  Normal organ and marrow function:

               -  No transfusions of packed red blood cells within 1 week of starting treatment

               -  Leukocytes greater or equal to 3,000/μL

                  ** White blood cell (WBC) greater or equal to 1,500/μL for patients with
                  hematologic malignancies

               -  Absolute neutrophil count (ANC) greater or equal to 1,500/μL

                  ** ANC greater or equal to 1,000/μL for patients with hematologic malignancies

               -  Platelets (PLT) greater or equal to 100,000/μL

                  ** PLT greater or equal to 50,000/μL for patients with hematologic malignancies

               -  Total bilirubin within normal institutional limits

               -  AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times institutional upper
                  limit of normal

               -  Serum triglycerides less than or equal to 500 mg/dl

               -  Creatinine within normal institutional limits OR creatinine clearance greater or
                  equal to 60 mL/min for patients with creatinine levels above institutional normal

          -  Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence)

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)
             prior to entering the study or those who have not recovered from adverse events due to
             agents administered more than 4 weeks earlier.

          -  May not be receiving any other investigational agents.

          -  Uncontrolled brain metastases or malignancy. Cannot be receiving enzyme-inducing
             anticonvulsants.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to rapamycin

          -  Gastrointestinal malabsorption syndromes, partial small bowel obstruction, or any
             illness that would interfere with the ability to absorb oral medications.

          -  Uncontrolled intercurrent illness

          -  Severe immunodeficient states (as judged by the treating physician)

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued.

          -  HIV-positive patients receiving combination antiretroviral therapy are excluded.

          -  Concurrent use of ketoconazole, cyclosporine, tacrolimus, diltiazem, and rifampin with
             rapamycin is not permissible. The concurrent use of calcium channel blockers,
             terfenadine, astemizole, cisapride, propafenone, cyclosporine, midazolam, triazolam,
             quinidine, or theophylline with grapefruit juice is not permissible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezra W Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2006</study_first_submitted>
  <study_first_submitted_qc>September 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2006</study_first_posted>
  <last_update_submitted>January 16, 2014</last_update_submitted>
  <last_update_submitted_qc>January 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase I</keyword>
  <keyword>metastatic</keyword>
  <keyword>advanced cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>renal cancer</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>esophagus</keyword>
  <keyword>GIST</keyword>
  <keyword>liver cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>mesothelioma</keyword>
  <keyword>lymphoma</keyword>
  <keyword>ovary cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>pancreas cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>thyroid cancer</keyword>
  <keyword>Metastatic solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

